brompheniramine (Rx, OTC)

Brand and Other Names:Dimetane, Respa-BR
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

tablet extended release

  • 11mg

oral suspension

  • 12mg/5mL

oral liquid

  • 1mg/1mL
  • 2 mg/5mL

Allergies

4 mg PO q4-6hr (no more than 24 mg qDay) PRN

Extended release: 8-12 mg tablet PO q12hr or 12-24 mg capsule PO qDay

Other Indications & Uses

Perennial & seasonal allergic & vasomotor rhinitis, relief of symptoms from colds, urticaria, angioedema, anaphylactic reactions, pruritus, allergic conjunctivitis

Dosage Forms & Strengths

tablet

  • 11mg

oral suspension

  • 12mg/5mL

liquid

  • 1mg/mL
  • 2mg/5mL

<12 Years Old

0.5 mg/kg/day divided q6hr PO  

Nonanticholinergic antihistamines should be considered first when treating allergic reactions (Beers Criteria)

Avoid use in elderly because of high incidence of anticholinergic effects

Clearance reduced with advanced age, greater risk of confusion, dry mouth, constipation, and other anticholinergic effects and toxicity

May exacerbate existing lower urinary conditions or benign prostatic hyperplasia

Next:

Interactions

Interaction Checker

and brompheniramine

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (8)

              • calcium/magnesium/potassium/sodium oxybates

                brompheniramine, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

              • eluxadoline

                brompheniramine, eluxadoline. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that cause constipation. Increases risk for constipation related serious adverse reactions.

              • isocarboxazid

                isocarboxazid increases effects of brompheniramine by Other (see comment). Avoid or Use Alternate Drug. Comment: Isocarboxazid should not be administered in combination with antihistamines because of potential additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. .

              • metoclopramide intranasal

                brompheniramine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.

              • pitolisant

                brompheniramine decreases effects of pitolisant by Other (see comment). Avoid or Use Alternate Drug. Comment: Pitolisant increases histamine levels in the brain; therefore, H1 receptor antagonists that cross the blood-brain barrier may reduce the efficacy of pitolisant.

              • selinexor

                selinexor, brompheniramine. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.

              • sodium oxybate

                brompheniramine, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

              • tranylcypromine

                tranylcypromine increases effects of brompheniramine by Other (see comment). Avoid or Use Alternate Drug. Comment: Tranylcypromine should not be administered in combination with antihistamines because of potential additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. .

              Monitor Closely (195)

              • albuterol

                brompheniramine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • alfentanil

                brompheniramine and alfentanil both increase sedation. Use Caution/Monitor.

              • alprazolam

                brompheniramine and alprazolam both increase sedation. Use Caution/Monitor.

              • amifampridine

                brompheniramine increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.

              • amitriptyline

                brompheniramine and amitriptyline both increase sedation. Use Caution/Monitor.

              • amobarbital

                brompheniramine and amobarbital both increase sedation. Use Caution/Monitor.

              • amoxapine

                brompheniramine and amoxapine both increase sedation. Use Caution/Monitor.

              • apomorphine

                brompheniramine and apomorphine both increase sedation. Use Caution/Monitor.

              • arformoterol

                brompheniramine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • aripiprazole

                brompheniramine and aripiprazole both increase sedation. Use Caution/Monitor.

              • armodafinil

                brompheniramine increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • azelastine

                azelastine and brompheniramine both increase sedation. Use Caution/Monitor.

              • baclofen

                brompheniramine and baclofen both increase sedation. Use Caution/Monitor.

              • belladonna and opium

                brompheniramine and belladonna and opium both increase sedation. Use Caution/Monitor.

              • benperidol

                brompheniramine and benperidol both increase sedation. Use Caution/Monitor.

              • benzphetamine

                brompheniramine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • brexanolone

                brexanolone, brompheniramine. Either increases toxicity of the other by sedation. Use Caution/Monitor.

              • buprenorphine

                brompheniramine and buprenorphine both increase sedation. Use Caution/Monitor.

              • buprenorphine buccal

                brompheniramine and buprenorphine buccal both increase sedation. Use Caution/Monitor.

              • butabarbital

                brompheniramine and butabarbital both increase sedation. Use Caution/Monitor.

              • butalbital

                brompheniramine and butalbital both increase sedation. Use Caution/Monitor.

              • butorphanol

                brompheniramine and butorphanol both increase sedation. Use Caution/Monitor.

              • caffeine

                brompheniramine increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • carbinoxamine

                brompheniramine and carbinoxamine both increase sedation. Use Caution/Monitor.

              • carisoprodol

                brompheniramine and carisoprodol both increase sedation. Use Caution/Monitor.

              • cenobamate

                cenobamate, brompheniramine. Either increases effects of the other by sedation. Use Caution/Monitor.

              • chloral hydrate

                brompheniramine and chloral hydrate both increase sedation. Use Caution/Monitor.

              • chlordiazepoxide

                brompheniramine and chlordiazepoxide both increase sedation. Use Caution/Monitor.

              • chlorpheniramine

                brompheniramine and chlorpheniramine both increase sedation. Use Caution/Monitor.

              • chlorpromazine

                brompheniramine and chlorpromazine both increase sedation. Use Caution/Monitor.

              • chlorzoxazone

                brompheniramine and chlorzoxazone both increase sedation. Use Caution/Monitor.

              • cinnarizine

                brompheniramine and cinnarizine both increase sedation. Use Caution/Monitor.

              • clemastine

                brompheniramine and clemastine both increase sedation. Use Caution/Monitor.

              • clobazam

                brompheniramine, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).

              • clomipramine

                brompheniramine and clomipramine both increase sedation. Use Caution/Monitor.

              • clonazepam

                brompheniramine and clonazepam both increase sedation. Use Caution/Monitor.

              • clorazepate

                brompheniramine and clorazepate both increase sedation. Use Caution/Monitor.

              • clozapine

                brompheniramine and clozapine both increase sedation. Use Caution/Monitor.

              • codeine

                brompheniramine and codeine both increase sedation. Use Caution/Monitor.

              • cyclizine

                brompheniramine and cyclizine both increase sedation. Use Caution/Monitor.

              • cyclobenzaprine

                brompheniramine and cyclobenzaprine both increase sedation. Use Caution/Monitor.

              • cyproheptadine

                brompheniramine and cyproheptadine both increase sedation. Use Caution/Monitor.

              • dantrolene

                brompheniramine and dantrolene both increase sedation. Use Caution/Monitor.

              • desflurane

                desflurane and brompheniramine both increase sedation. Use Caution/Monitor.

              • desipramine

                brompheniramine and desipramine both increase sedation. Use Caution/Monitor.

              • deutetrabenazine

                brompheniramine and deutetrabenazine both increase sedation. Use Caution/Monitor.

              • dexchlorpheniramine

                brompheniramine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

              • dexfenfluramine

                brompheniramine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dexmedetomidine

                brompheniramine and dexmedetomidine both increase sedation. Use Caution/Monitor.

              • dexmethylphenidate

                brompheniramine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dextroamphetamine

                brompheniramine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dextromoramide

                brompheniramine and dextromoramide both increase sedation. Use Caution/Monitor.

              • diamorphine

                brompheniramine and diamorphine both increase sedation. Use Caution/Monitor.

              • diazepam

                brompheniramine and diazepam both increase sedation. Use Caution/Monitor.

              • diazepam intranasal

                diazepam intranasal, brompheniramine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.

              • diethylpropion

                brompheniramine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • difenoxin hcl

                brompheniramine and difenoxin hcl both increase sedation. Use Caution/Monitor.

              • dimenhydrinate

                brompheniramine and dimenhydrinate both increase sedation. Use Caution/Monitor.

              • diphenhydramine

                brompheniramine and diphenhydramine both increase sedation. Use Caution/Monitor.

              • diphenoxylate hcl

                brompheniramine and diphenoxylate hcl both increase sedation. Use Caution/Monitor.

              • dipipanone

                brompheniramine and dipipanone both increase sedation. Use Caution/Monitor.

              • dobutamine

                brompheniramine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dopamine

                brompheniramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dopexamine

                brompheniramine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dosulepin

                brompheniramine and dosulepin both increase sedation. Use Caution/Monitor.

              • doxepin

                brompheniramine and doxepin both increase sedation. Use Caution/Monitor.

              • doxylamine

                brompheniramine and doxylamine both increase sedation. Use Caution/Monitor.

              • droperidol

                brompheniramine and droperidol both increase sedation. Use Caution/Monitor.

              • ephedrine

                brompheniramine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • epinephrine

                brompheniramine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • epinephrine racemic

                brompheniramine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • esketamine intranasal

                esketamine intranasal, brompheniramine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.

              • estazolam

                brompheniramine and estazolam both increase sedation. Use Caution/Monitor.

              • ethanol

                brompheniramine and ethanol both increase sedation. Use Caution/Monitor.

              • etomidate

                etomidate and brompheniramine both increase sedation. Use Caution/Monitor.

              • fenfluramine

                brompheniramine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • fentanyl

                fentanyl, brompheniramine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

              • fentanyl intranasal

                fentanyl intranasal, brompheniramine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

              • fentanyl transdermal

                fentanyl transdermal, brompheniramine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

              • fentanyl transmucosal

                fentanyl transmucosal, brompheniramine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

              • flibanserin

                brompheniramine and flibanserin both increase sedation. Modify Therapy/Monitor Closely. Risk for sedation increased if flibanserin is coadministration with other CNS depressants.

              • fluphenazine

                brompheniramine and fluphenazine both increase sedation. Use Caution/Monitor.

              • flurazepam

                brompheniramine and flurazepam both increase sedation. Use Caution/Monitor.

              • formoterol

                brompheniramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • gabapentin

                gabapentin, brompheniramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.

              • gabapentin enacarbil

                gabapentin enacarbil, brompheniramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.

              • glycopyrronium tosylate topical

                glycopyrronium tosylate topical, brompheniramine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.

              • gotu kola

                gotu kola increases effects of brompheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • haloperidol

                brompheniramine and haloperidol both increase sedation. Use Caution/Monitor.

              • hawthorn

                hawthorn increases effects of brompheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • hops

                hops increases effects of brompheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • hyaluronidase

                brompheniramine decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. Comment: Antihistamines, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect.

              • hydromorphone

                brompheniramine and hydromorphone both increase sedation. Use Caution/Monitor.

              • hydroxyzine

                brompheniramine and hydroxyzine both increase sedation. Use Caution/Monitor.

              • iloperidone

                brompheniramine and iloperidone both increase sedation. Use Caution/Monitor.

              • imipramine

                brompheniramine and imipramine both increase sedation. Use Caution/Monitor.

              • isoproterenol

                brompheniramine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • kava

                kava increases effects of brompheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • ketamine

                ketamine and brompheniramine both increase sedation. Use Caution/Monitor.

              • ketotifen, ophthalmic

                brompheniramine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.

              • lasmiditan

                lasmiditan, brompheniramine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.

              • lemborexant

                lemborexant, brompheniramine. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.

              • levalbuterol

                brompheniramine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • levorphanol

                brompheniramine and levorphanol both increase sedation. Use Caution/Monitor.

              • lisdexamfetamine

                brompheniramine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • lofepramine

                brompheniramine and lofepramine both increase sedation. Use Caution/Monitor.

              • lofexidine

                brompheniramine and lofexidine both increase sedation. Use Caution/Monitor.

              • loprazolam

                brompheniramine and loprazolam both increase sedation. Use Caution/Monitor.

              • lorazepam

                brompheniramine and lorazepam both increase sedation. Use Caution/Monitor.

              • lormetazepam

                brompheniramine and lormetazepam both increase sedation. Use Caution/Monitor.

              • loxapine

                brompheniramine and loxapine both increase sedation. Use Caution/Monitor.

              • loxapine inhaled

                brompheniramine and loxapine inhaled both increase sedation. Use Caution/Monitor.

              • lurasidone

                lurasidone, brompheniramine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.

              • maprotiline

                brompheniramine and maprotiline both increase sedation. Use Caution/Monitor.

              • marijuana

                brompheniramine and marijuana both increase sedation. Use Caution/Monitor.

              • melatonin

                brompheniramine and melatonin both increase sedation. Use Caution/Monitor.

              • meperidine

                brompheniramine and meperidine both increase sedation. Use Caution/Monitor.

              • meprobamate

                brompheniramine and meprobamate both increase sedation. Use Caution/Monitor.

              • metaproterenol

                brompheniramine increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • metaxalone

                brompheniramine and metaxalone both increase sedation. Use Caution/Monitor.

              • methadone

                brompheniramine and methadone both increase sedation. Use Caution/Monitor.

              • methamphetamine

                brompheniramine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • methocarbamol

                brompheniramine and methocarbamol both increase sedation. Use Caution/Monitor.

              • methylenedioxymethamphetamine

                brompheniramine increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • midazolam

                brompheniramine and midazolam both increase sedation. Use Caution/Monitor.

              • midazolam intranasal

                midazolam intranasal, brompheniramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.

              • midodrine

                brompheniramine increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • mirtazapine

                brompheniramine and mirtazapine both increase sedation. Use Caution/Monitor.

              • modafinil

                brompheniramine increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • morphine

                brompheniramine and morphine both increase sedation. Use Caution/Monitor.

              • motherwort

                brompheniramine and motherwort both increase sedation. Use Caution/Monitor.

              • moxonidine

                brompheniramine and moxonidine both increase sedation. Use Caution/Monitor.

              • nabilone

                brompheniramine and nabilone both increase sedation. Use Caution/Monitor.

              • nalbuphine

                brompheniramine and nalbuphine both increase sedation. Use Caution/Monitor.

              • norepinephrine

                brompheniramine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • nortriptyline

                brompheniramine and nortriptyline both increase sedation. Use Caution/Monitor.

              • olanzapine

                brompheniramine and olanzapine both increase sedation. Use Caution/Monitor.

              • opium tincture

                brompheniramine and opium tincture both increase sedation. Use Caution/Monitor.

              • orphenadrine

                brompheniramine and orphenadrine both increase sedation. Use Caution/Monitor.

              • oxazepam

                brompheniramine and oxazepam both increase sedation. Use Caution/Monitor.

              • oxycodone

                brompheniramine and oxycodone both increase sedation. Use Caution/Monitor.

              • oxymorphone

                brompheniramine and oxymorphone both increase sedation. Use Caution/Monitor.

              • paliperidone

                brompheniramine and paliperidone both increase sedation. Use Caution/Monitor.

              • papaveretum

                brompheniramine and papaveretum both increase sedation. Use Caution/Monitor.

              • papaverine

                brompheniramine and papaverine both increase sedation. Use Caution/Monitor.

              • passion flower

                passion flower increases effects of brompheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • pentazocine

                brompheniramine and pentazocine both increase sedation. Use Caution/Monitor.

              • pentobarbital

                brompheniramine and pentobarbital both increase sedation. Use Caution/Monitor.

              • perampanel

                perampanel and brompheniramine both increase sedation. Use Caution/Monitor.

              • perphenazine

                brompheniramine and perphenazine both increase sedation. Use Caution/Monitor.

              • phendimetrazine

                brompheniramine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • phenelzine

                phenelzine increases effects of brompheniramine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Coadministration of phenelzine and antihistamines may result in additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. .

              • phenobarbital

                brompheniramine and phenobarbital both increase sedation. Use Caution/Monitor.

              • phentermine

                brompheniramine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • phenylephrine

                brompheniramine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • phenylephrine PO

                brompheniramine increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .

              • pholcodine

                brompheniramine and pholcodine both increase sedation. Use Caution/Monitor.

              • pimozide

                brompheniramine and pimozide both increase sedation. Use Caution/Monitor.

              • pirbuterol

                brompheniramine increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • pregabalin

                pregabalin, brompheniramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.

              • primidone

                brompheniramine and primidone both increase sedation. Use Caution/Monitor.

              • prochlorperazine

                brompheniramine and prochlorperazine both increase sedation. Use Caution/Monitor.

              • promethazine

                brompheniramine and promethazine both increase sedation. Use Caution/Monitor.

              • propofol

                propofol and brompheniramine both increase sedation. Use Caution/Monitor.

              • propylhexedrine

                brompheniramine increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • protriptyline

                brompheniramine and protriptyline both increase sedation. Use Caution/Monitor.

              • quazepam

                brompheniramine and quazepam both increase sedation. Use Caution/Monitor.

              • quetiapine

                brompheniramine and quetiapine both increase sedation. Use Caution/Monitor.

              • ramelteon

                brompheniramine and ramelteon both increase sedation. Use Caution/Monitor.

              • risperidone

                brompheniramine and risperidone both increase sedation. Use Caution/Monitor.

              • salmeterol

                brompheniramine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • scullcap

                brompheniramine and scullcap both increase sedation. Use Caution/Monitor.

              • secobarbital

                brompheniramine and secobarbital both increase sedation. Use Caution/Monitor.

              • sevoflurane

                sevoflurane and brompheniramine both increase sedation. Use Caution/Monitor.

              • shepherd's purse

                brompheniramine and shepherd's purse both increase sedation. Use Caution/Monitor.

              • sufentanil

                brompheniramine and sufentanil both increase sedation. Use Caution/Monitor.

              • tapentadol

                brompheniramine and tapentadol both increase sedation. Use Caution/Monitor.

              • temazepam

                brompheniramine and temazepam both increase sedation. Use Caution/Monitor.

              • terbutaline

                brompheniramine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • thioridazine

                brompheniramine and thioridazine both increase sedation. Use Caution/Monitor.

              • thiothixene

                brompheniramine and thiothixene both increase sedation. Use Caution/Monitor.

              • topiramate

                brompheniramine and topiramate both increase sedation. Modify Therapy/Monitor Closely.

              • tramadol

                brompheniramine and tramadol both increase sedation. Use Caution/Monitor.

              • trazodone

                brompheniramine and trazodone both increase sedation. Use Caution/Monitor.

              • triazolam

                brompheniramine and triazolam both increase sedation. Use Caution/Monitor.

              • triclofos

                brompheniramine and triclofos both increase sedation. Use Caution/Monitor.

              • trifluoperazine

                brompheniramine and trifluoperazine both increase sedation. Use Caution/Monitor.

              • trimipramine

                brompheniramine and trimipramine both increase sedation. Use Caution/Monitor.

              • triprolidine

                brompheniramine and triprolidine both increase sedation. Use Caution/Monitor.

              • valerian

                valerian increases effects of brompheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • xylometazoline

                brompheniramine increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • yohimbine

                brompheniramine increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • ziconotide

                brompheniramine and ziconotide both increase sedation. Use Caution/Monitor.

              • ziprasidone

                brompheniramine and ziprasidone both increase sedation. Use Caution/Monitor.

              • zotepine

                brompheniramine and zotepine both increase sedation. Use Caution/Monitor.

              Minor (6)

              • ashwagandha

                ashwagandha increases effects of brompheniramine by pharmacodynamic synergism. Minor/Significance Unknown. May enhance CNS depression.

              • brimonidine

                brimonidine increases effects of brompheniramine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • eucalyptus

                brompheniramine and eucalyptus both increase sedation. Minor/Significance Unknown.

              • nettle

                nettle increases effects of brompheniramine by pharmacodynamic synergism. Minor/Significance Unknown. (High dose nettle; theoretical interaction) May enhance CNS depression.

              • sage

                brompheniramine and sage both increase sedation. Minor/Significance Unknown.

              • Siberian ginseng

                Siberian ginseng increases effects of brompheniramine by pharmacodynamic synergism. Minor/Significance Unknown. May enhance CNS depression.

              Previous
              Next:

              Adverse Effects

              Varies in incidence & severity with the individual drug; also individual patients vary in susceptibility

              Frequency Not Defined

              CNS depression

              Drowsiness

              Sedation ranging from mild drowsiness to deep sleep (most frequent)

              Dizziness

              Lassitude

              Disturbed coordination

              Muscular weakness

              Restlessness, insomnia, tremors, euphoria, nervousness, delirium, palpitation, seizures is less common

              Epigastric distress

              Anorexia

              Nausea

              Vomiting

              Diarrhea

              Constipation

              Cholestasis, hepatitis, hepatic failure, hepatic function abnormality, jaundice is rare

              Tachycardia, palpitation ECG changes (eg, widened QRS)

              Arrhythmias (eg, extrasystole, heart block)

              Hypotension

              Hypertension

              Dizziness, sedation, and hypotension may occur in geriatric patients

              Dryness of mouth, nose, and throat

              Dysuria

              Urinary retention

              Impotence

              Vertigo

              Visual disturbances

              Blurred vision

              Diplopia; tinnitus

              Acute labyrinthitis

              Insomnia

              Tremors

              Nervousness

              Irritability

              Facial dyskinesia

              Tightness of the chest

              Thickening of bronchial secretions

              Wheezing

              Nasal stuffiness

              Sweating

              Chills

              Early menses

              Toxic psychosis

              Headache

              Faintness

              Paresthesia

              Agranulocytosis

              Hemolytic anemia

              Leukopenia

              Thrombocytopenia

              Pancytopenia

              Previous
              Next:

              Warnings

              Contraindications

              Documented hypersensitivity

              Lower respiratory disease, eg, asthma (controversial)

              Preemies & neonates

              Nursing women

              Caution

              Caution in narrow angle glaucoma, prostatic hypertrophy, stenosing peptic ulcer, pyloroduodenal obstruction, or bladder neck obstruction

              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy Category: C

              Lactation: excretion in milk unknown/contraindicated

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Mechanism of Action

              Histamine H1-receptor antagonist

              Pharmacokinetics

              Half-Life: 11.8-34.7 hr

              Onset: 30 min

              Peak Plasma Time: 2-5 hr

              Vd: 11.7 L/kg

              Metabolism: mainly liver

              Metabolites: Propionic acid derivative conjugated with glycine

              Excretion: urine

              Antihistamine activity: high

              Sedative effect: Low

              Anticholinergic effects: Moderate

              Duration

              • Antihistamine: 3-9 hr, may last 48 hr
              • Antipruritic: 9-24 hr
              Previous
              Next:

              Images

              No images available for this drug.
              Previous
              Next:

              Patient Handout

              A Patient Handout is not currently available for this monograph.
              Previous
              Next:

              Formulary

              FormularyPatient Discounts

              Adding plans allows you to compare formulary status to other drugs in the same class.

              To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

              Adding plans allows you to:

              • View the formulary and any restrictions for each plan.
              • Manage and view all your plans together – even plans in different states.
              • Compare formulary status to other drugs in the same class.
              • Access your plan list on any device – mobile or desktop.

              The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

              Tier Description
              1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
              2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
              3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
              4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              NC NOT COVERED – Drugs that are not covered by the plan.
              Code Definition
              PA Prior Authorization
              Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
              QL Quantity Limits
              Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
              ST Step Therapy
              Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
              OR Other Restrictions
              Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
              Additional Offers
              Email to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Email Forms to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.